294 related articles for article (PubMed ID: 33579850)
1. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
Wang J; Guo X; Lu W; Liu J; Zhang H; Quan Q; Su H; Ma L; Gao F; Qu Q
J Alzheimers Dis; 2021; 80(2):673-681. PubMed ID: 33579850
[TBL] [Abstract][Full Text] [Related]
2. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial.
Jia J; Wei C; Liang J; Zhou A; Zuo X; Song H; Wu L; Chen X; Chen S; Zhang J; Wu J; Wang K; Chu L; Peng D; Lv P; Guo H; Niu X; Chen Y; Dong W; Han X; Fang B; Peng M; Li D; Jia Q; Huang L
Alzheimers Dement; 2016 Feb; 12(2):89-99. PubMed ID: 26086183
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
[TBL] [Abstract][Full Text] [Related]
4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease.
Li DD; Zhang YH; Zhang W; Zhao P
Front Neurosci; 2019; 13():472. PubMed ID: 31156366
[TBL] [Abstract][Full Text] [Related]
6. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
10. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
11. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
12. Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.
Jia Y; Zhang X; Yu J; Han J; Yu T; Shi J; Zhao L; Nie K
BMC Complement Altern Med; 2017 Dec; 17(1):556. PubMed ID: 29284465
[TBL] [Abstract][Full Text] [Related]
13. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
14. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
15. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
17. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.
Ferris SH; Schmitt FA; Saxton J; Richardson S; Mackell J; Sun Y; Xu Y
Alzheimers Res Ther; 2011 Jun; 3(3):22. PubMed ID: 21689411
[TBL] [Abstract][Full Text] [Related]
18. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
Li DQ; Zhou YP; Yang H
Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
[TBL] [Abstract][Full Text] [Related]
19. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
20. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
Rockwood K; Fay S; Gorman M; Carver D; Graham JE
BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
